The Impact of AI on Oncology Care Efficiency and Mortality Rates

The principal advantage of integrating AI into diagnostics lies in melanoma and breast cancer screening, where early detection stands as the pivotal factor influencing favorable mortality and morbidity outcomes. Regrettably, AI is plagued by profound biases associated with its training, significantly impeding its application in the field.

The underrepresentation of training data, coupled with disparities in data presentation and variability in data acquisition and processing, renders most AI models non-generalizable. This, in turn, obstructs their integration into global oncology protocols.

“Modifications along the algorithm development pipeline can help mitigate these concerns. Training data can be expanded to include representative images from all demographics (e.g. skin color, ages, and body types). Training sets with image data should include samples taken from different angles, lighting, and equipment; and AI technologies should accommodate changes in image acquisition technology by retraining the model with new images.”

Prognostication:

Anticipating patient outcomes stands as one of the paramount initial clinical intervention measures undertaken by medical practitioners. This enables the customization of clinical interventions to enhance or avert the most adverse clinical consequences.

Regrettably, prognostication conducted by humans has historically been prone to significant inaccuracies. Reports suggest that 63% of prognoses tend to overestimate outcomes, while 17% underestimate patient survival.

“The consequences of inaccurate predictions in oncology include increased emotional burden on patients and their caregivers, inappropriate allocation of resources, decreased trust in the patient–physician relationship, and delay in crucial therapeutic or end-of-life interventions. AI-based risk prediction models that generate individualized estimates on prognosis have augmented clinician assessments of risk and aided personalized care decisions in oncology.”

Electronic health records (EHR)-based machine learning (ML) models exhibit tremendous potential in this realm. They have demonstrated the ability to forecast cancer outcomes months or even years in advance, equipping clinicians with the foresight necessary to adequately prepare for oncological eventualities.

Furthermore, these models possess the capability to assess the most efficient and cost-effective clinical intervention pathway, thereby conserving substantial clinical manpower and minimizing patients’ financial outlay, consequently alleviating the overall disease and socioeconomic burden.

Alas, the deterministic nature of most of these models renders them vulnerable to alterations in model outcomes upon the incorporation of novel, yet unaccounted for, data generation methodologies.

The phenomenon known as ‘performance drift,’ characterized by the gradual deterioration in model efficacy over time, may render subsequent model predictions inaccurate and unreliable unless regular updates to the modeling algorithm and rigorous human results validation are diligently conducted.

In this arena, the quality of training data, frequent human model validation, and cross-cancer data-sharing initiatives may serve as potential remedies to overcome these challenges in the future.

Chatbots and Conclusions: Cutting-edge conversational chatbots, epitomized by platforms such as ChatGPT, Google Gemini, Microsoft Copilot, and others, are redefining the landscape of information acquisition and processing for both professionals and laypersons across the World Wide Web.

These generative AI applications harness the prowess of large language models to generate novel content tailored to the user’s requirements.

Regrettably, exploration of chatbot applications in oncology indicates that the technology is still in its infancy, lacking adequate support and, more critically, lacking policy-sanctioned implementation in clinical settings.

“The adoption of chatbots for medicine relies on achieving both understandable language and conveying complex medical topics accurately, which current algorithms cannot do consistently because readability scores vary by the user’s verbiage of the prompt. Although medical knowledge expands each day, algorithms are not continuously updated to accommodate this change. As a result, the chatbots that are not trained on updated information can become unreliable and more inaccurate with time.”

Collectively, these individual, discipline-specific advantages and disadvantages portray a compelling narrative – while the significance and pertinence of AI integration in oncological research are undeniable, the computational and raw data requisites of these models have only recently begun to be fulfilled.

With the advancement of enhanced modeling frameworks, the availability of larger and more detailed datasets, and the heightened scientific validation of their precision and dependability, AI models emerge as potent instruments in the oncologist’s arsenal against this formidable ailment and hold the potential to alleviate the majority of the burden associated with cancer care from human medical practitioners in the foreseeable future.

For more information: Uses and limitations of artificial intelligence for oncology, Journal Cancer, https://doi.org/10.1002/cncr.35307